Study guide
Cervical screening and cervical cancer
AMC CAT MCQ Examination AMC Part 1
Track your progress as you read
Finished sections get a check mark.
1 Acute Coronary Syndromes & ECG Localization
ACS recognition and ECG localisation Reperfusion and infarction complications
2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias
Heart failure assessment and treatment Arrhythmias and conduction emergencies
3 Systemic Hypertension & Peripheral Vascular Disease
Blood pressure and cardiovascular risk Secondary hypertension and arterial disease
4 Valvular Heart Disease, Infective Endocarditis & Pericarditis
Aortic and mitral valve disease Endocarditis and pericardial emergencies
5 Asthma & COPD Acute Flares and Maintenance
Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations
6 Pneumonia, pleural disease and respiratory failure
Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis
7 GI bleeding, bowel inflammation and malabsorption
GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS
8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis
Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance
9 Diabetes, thyroid and adrenal disease
Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease
10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies
AKI and chronic kidney disease Potassium and sodium emergencies
11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment
Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care
12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis
Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia
13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology
Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms
14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis
Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment
15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries
Trauma primary survey and adjuncts Chest trauma and immediate threats
16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance
Head injury, imaging and haemorrhage Herniation and spinal cord injury
17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome
Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury
18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care
Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus
19 Aortic Aneurysms & Acute Arterial Limb Ischaemia
Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia
20 Urological Emergencies, Testicular Torsion & Haematuria Investigation
Retention, stones and obstructed infection Scrotal pain and haematuria
21 Preoperative Risk Stratification & Postoperative Surgical Complications
Preoperative assessment and medicines Postoperative complications and prevention
22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening
Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons
23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy
Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding
24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies
Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth
25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis
Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care
26 Contraception, Emergency Contraception & Pregnancy Termination
Contraceptive choice and missed pills Emergency contraception and abortion
27 Australian Cervical Screening Program & Gynaecological Malignancies
Cervical screening and cervical cancer Endometrial and ovarian cancer
28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice
Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening
29 Developmental Milestones, Growth Charts & Failure to Thrive
Developmental milestones Regression, autism and support Faltering growth and developmental comparisons
30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions
Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons
31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis
Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis
32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease
Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up
33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury
Pyloric stenosis Intussusception and dehydration Child protection and injury assessment
34 The Mental State Examination & Suicide Risk Stratification
Mental state examination and psychotic symptoms Suicide formulation and mental health law
35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers
Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT
36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder
Anxiety, panic and agoraphobia OCD and trauma-related disorders
37 Schizophrenia, Acute Psychosis & Antipsychotic Management
Psychosis assessment and antipsychotics Clozapine and severe adverse effects
38 Substance Use Disorders & Acute Withdrawal Syndromes
Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants
39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry
Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry
40 Medicare, PBS, AHPRA & Good Medical Practice Framework
Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications
41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment
Consent, material risks and young people Capacity, refusal and substitute decisions
42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications
Privacy, disclosure and child reporting Driving fitness and threat disclosure
43 First Nations health and preventive care
First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention
44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases
Epidemiology, calculations, bias and surveillance
45 Neurological presentations
Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness
46 Musculoskeletal pain
Back, neck, bone and soft tissue pain
47 Eye presentations
Altered vision and retinal disease Red eye, ocular injury and discharge
48 Ear, nose, throat and oral health
Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis
49 Skin, hair and nails
Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities
50 Breast health and feeding
Breast lumps, discharge and breastfeeding problems
51 Sexual and reproductive presentations
Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction
52 Palliative care and carers
The dying patient, symptoms and carers
53 Eating disorders and personality care
Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care
54 Sleep presentations
Insomnia, snoring and daytime sleepiness
55 Poisoning, resuscitation and environmental emergencies
Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning
56 Communication, rights and professional practice
Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health
57 Genetics, research and donation
Genetic testing, research and organ donation
58 Travel, fever and outbreaks
Fever, travellers and outbreak response
Cervical screening and cervical cancer
Key Takeaways Explain This Topic AI
Routine cervical screening applies from age 25 to 74 in eligible people with a cervix.
HPV16/18 detection generally requires colposcopic assessment.
Bleeding symptoms require diagnostic assessment rather than routine screening alone.
Last updated: October 2026
Australian Cervical Screening Program & Gynaecological Malignancies
Gynaecological oncology encompasses the prevention, early detection, and multidisciplinary treatment of malignancies of the cervix, endometrium, and ovary. In Australia, population-based screening has transformed cervical cancer epidemiology, while transvaginal ultrasound triage protocols and biomarker stratification govern the management of postmenopausal bleeding and suspicious pelvic masses.
The Australian National Cervical Screening Program (NCSP)
In December 2017, Australia transitioned from 2-yearly conventional Papanicolaou cytology to 5-yearly primary human papillomavirus (HPV) nucleic acid testing , a change that significantly improved sensitivity for detecting high-grade cervical intraepithelial neoplasia (CIN 2/3) and adenocarcinoma in situ (AIS).
Target Population & Collection Modalities
Eligible Cohort : Asymptomatic individuals with a cervix aged 25 to 74 years (commencing at age 25, exit screening between ages 70 and 74 if prior tests were negative).
Clinician-Collected Sample : Performed via speculum examination using a cervical broom or brush to sample the transformation zone (the squamocolumnar junction), rinsed into liquid-based cytology (LBC) transport medium (ThinPrep).
Self-Collected Vaginal Swab : Available since July 2022 to all eligible screening participants as an empowered, universal choice. Performed using a dry flocked swab inserted into the mid-vagina. Polymerase chain reaction (PCR) assays demonstrate equivalent clinical sensitivity and specificity for oncogenic HPV detection compared to clinician collection. If oncogenic HPV (non-16/18) is detected on a self-collected sample, the patient must attend for a speculum examination to obtain cervical cells for reflex LBC before clinical management is determined.
Triage Algorithm and Referral Guidelines
Low Risk (Oncogenic HPV Not Detected) :
Return to routine screening in 5 years .
High Risk (Oncogenic HPV Types 16 and/or 18 Detected) :
HPV 16 and 18 are responsible for > 70 % > 70\% > 70% of cervical cancers and carry the highest immediate risk of high-grade disease.
Mandatory direct referral for colposcopy , regardless of the reflex LBC result (even if LBC is completely normal/negative).
Intermediate Risk (Oncogenic HPV Non-16/18 Detected) :
Includes oncogenic types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. The laboratory automatically performs reflex liquid-based cytology (LBC) on the collected sample:
LBC Negative or Low-Grade Squamous Intraepithelial Lesion (p-LSIL / LSIL) : Advise the patient to have a repeat HPV test in 12 months in general practice.
Twelve-month follow-up: HPV negative generally returns to routine five-year screening. Persistent non-16/18 HPV with negative/low-grade LBC usually has another twelve-month follow-up; First Nations participants, those at least fifty and substantially underscreened patients can need colposcopy at this point. Persistent HPV at twenty-four months warrants colposcopy. Use the current history-specific NCSP pathway.
LBC High-Grade Squamous Intraepithelial Lesion (p-HSIL / HSIL) , Atypical Squamous Cells Cannot Exclude HSIL (ASC-H) , Atypical Glandular/Endocervical Cells , or Suspicion of Microinvasive/Invasive Carcinoma : Immediate referral for colposcopy .
Symptomatic Women Exempt from Screening Pathways
Symptoms require diagnostic assessment, including examination and an appropriate co-test rather than routine self-screening. Persistent/recurrent postcoital bleeding, a visible lesion or abnormal examination needs referral. A single episode with a normal cervix and negative co-test does not always require gynaecological referral. Persistent unexplained discharge or postmenopausal bleeding requires its own assessment regardless of a recent screening result.
- Cervical Carcinoma
- Epidemiology & Histopathology
Persistent high-risk oncogenic HPV infection is the necessary cause of > 99 % > 99\% > 99% of cervical cancers. Viral oncoproteins E6 (which binds and accelerates the degradation of the tumour suppressor protein p53) and E7 (which binds and inactivates the retinoblastoma tumour suppressor protein pRb) drive unchecked cell cycle progression and genomic instability.
Squamous Cell Carcinoma (SCC) : Accounts for 70% to 80% of cases, arising at the transformation zone.
Adenocarcinoma : Accounts for 20% to 25% of cases, arising from endocervical columnar epithelium (disproportionately associated with HPV 18). Its relative incidence has increased because cytology is less sensitive at sampling the endocervical canal.
Clinical Presentation
Early-stage carcinoma is frequently asymptomatic, underscoring the role of the NCSP.
The cardinal presenting symptom is postcoital bleeding (PCB) , followed by intermenstrual bleeding, postmenopausal bleeding, and offensive serosanguinous vaginal discharge.
Advanced lesions produce pelvic pain radiating to the sacrum, sciatic nerve pain, lower extremity oedema (from iliac venous compression or lymphatic obstruction), and oliguria/uraemia from bilateral ureteric obstruction.
FIGO Staging and Management
Staging is clinical and pathological, incorporating cross-sectional imaging (pelvic MRI and whole-body PET-CT):
Stage I : Confined strictly to the cervix uteri (IA: microscopic depth < 5 mm < 5\text{ mm} < 5 mm ; IB: depth ≥ 5 mm \ge 5\text{ mm} ≥ 5 mm or clinically visible lesion confined to cervix).
Stage II : Extends beyond the cervix but not to the pelvic sidewall or lower third of the vagina (IIA: upper two-thirds of vagina; IIB: parametrial infiltration).
Stage III : Involves the lower third of the vagina (IIIA), extends to the pelvic sidewall or causes hydronephrosis (IIIB), or involves pelvic/para-aortic lymph nodes (IIIC).
Stage IV : Infiltrates the mucosa of the bladder or rectum (IVA) or extends to distant metastatic organs (IVB).
Therapeutic Principles
Early Stage (Stage IA1 without lymphovascular space invasion) : Conservative fertility-sparing cervical conization or simple hysterectomy.
Cervical treatment: Stage, size, nodes and fertility goals determine surgery versus chemoradiation. Selected early low-risk disease may have less radical surgery; do not apply radical hysterectomy to every early lesion.
Locally Advanced Disease (Stage IB3 to IVA) : Definitive concurrent chemoradiotherapy (external beam pelvic radiotherapy with concurrent weekly intravenous cisplatin , followed by high-dose-rate intracavitary brachytherapy ). Primary surgical resection is strictly contraindicated in locally advanced disease due to excessive morbidity and inferior overall survival compared to chemoradiotherapy.
Primary references (checked 7 October 2026): National cervical screening provider resources .